BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20509125)

  • 1. [Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients].
    Burger S; Lehnert M; Ludwig H
    Ther Umsch; 2010 May; 67(5):271-6. PubMed ID: 20509125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating protein support and survival.
    Crawford J
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):39-43. PubMed ID: 16925111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of erythropoiesis stimulating agents].
    Lapierre A; Souquet PJ
    Rev Mal Respir; 2014 Feb; 31(2):162-72. PubMed ID: 24602683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.
    Spano JP; Khayat D
    Oncologist; 2008; 13 Suppl 3():27-32. PubMed ID: 18458122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia in cancer patients: significance, epidemiology, and current therapy.
    Tchekmedyian NS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
    Crawford J
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-related anaemia management in the 21st century.
    Pronzato P
    Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.
    Hershman DL; Buono DL; Malin J; McBride R; Tsai WY; Neugut AI
    J Natl Cancer Inst; 2009 Dec; 101(23):1633-41. PubMed ID: 19903808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chemotherapy-induced anemia.
    Eguchi K
    Curr Opin Oncol; 1995 Jul; 7(4):316-9. PubMed ID: 7578378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with beta-erythropoietin in lung cancer--effectiveness and quality of life improvement in clinical practice].
    Tamási L; Gálffy G
    Orv Hetil; 2010 Oct; 151(41):1684-8. PubMed ID: 20880802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
    Lyman GH
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):16-20. PubMed ID: 16925106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ESAs further restricted, but debate continues.
    Brower V
    J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.